UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported):
November 3, 2015
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
001-34566 |
75-2308816 |
(State or other jurisdiction of |
(Commission File No.) |
(IRS Employer ID No.) |
incorporation or organization) |
|
|
18th Floor, Jialong International Building |
19 Chaoyang Park Road |
Chaoyang District, Beijing 100125 |
People’s Republic of China |
(Address of Principal Executive Offices)
86-10-6598-3166
Registrant's telephone number, including
area code
____________________________________________________________
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c)) |
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On November 3, 2015, China Biologic Products, Inc. (the “Company”)
issued a press release announcing its unaudited financial results for its third quarter ended September 30, 2015. A copy of the
press release, which the Company is furnishing to the Securities and Exchange Commission, is attached as Exhibit 99.1 and incorporated
by reference herein.
The information contained in this Current Report on Form 8-K
and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information
or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 7.01 REGULATION FD DISCLOSURE.
The information set forth in Item 2.02 above is incorporated
by reference herein.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit
Number |
Description |
|
|
99.1 |
Press release dated November 3, 2015 |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 3, 2015 |
CHINA BIOLOGIC PRODUCTS, INC. |
|
|
|
|
|
By: |
/s/ David (Xiaoying) Gao |
|
|
|
David (Xiaoying) Gao |
|
|
|
Chief Executive Officer |
|
Exhibit 99.1
![](http://www.sec.gov/Archives/edgar/data/1369868/000114420415062532/image_001.jpg)
FOR RELEASE November 3, 2015
China Biologic Reports Financial Results
for the Third Quarter of 2015
3Q15 Total Sales Up 14.4% YoY to $78.8
Million
3Q15 Non-GAAP Net Income Up 23.6% YoY
to $26.2 Million
9M15 Total Sales Up 23.2% YoY to $228.2
Million
9M15 Non-GAAP Net Income Up 31.1% YoY
to $79.7 Million
Raises Forecast for FY15 Non-GAAP Adjusted
Net Income
BEIJING, China – November 3,
2015 – China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading
fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the third
quarter of 2015.
Third Quarter 2015 Financial Highlights
| · | Total
sales in the third quarter of 2015 increased by 14.4% to $78.8 million from $68.9
million in the same quarter of 2014. |
| · | Gross
profit increased by 9.0% to $50.8 million from $46.6 million in the same quarter
of 2014. Gross margin decreased by 3.1 basis points to 64.5% in the third quarter
of 2015 from 67.6% in the third quarter of 2014. |
| · | Income
from operations increased by 1.2% to $35.0 million from $34.6 million in the same
quarter of 2014. Operating margin decreased to 44.5% in the third quarter of 2015
from 50.2% in the same quarter of 2014. |
| · | Net
income attributable to the Company increased by 13.9% to $22.9 million from $20.1
million in the same quarter of 2014. Fully diluted net income per share increased
to $0.82 from $0.76 in the same quarter of 2014. |
| · | Non-GAAP
adjusted net income attributable to the Company increased by 23.6% to $26.2 million
from $21.2 million in the same quarter of 2014. Non-GAAP adjusted net income per share
increased to $0.94 from $0.81 in the same quarter of 2014. |
Mr. David
(Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, “We are pleased to report another healthy
quarter that exceeded our expectations, despite a slightly negative impact from foreign currency
translation, as we were able to sell a greater volume of finished products made from the purchased plasma than we originally anticipated
and benefited from modestly better product pricing. During this quarter, market demand for plasma products remained strong and
we continued to make progress on our further penetration into tier-one markets. As we announced last quarter, we expected to experience
a lower year-over-year growth rate in the third quarter compared to the first half of the year, due to a relatively high volume
sold in the third quarter of 2014 following the first batch approval from the upgraded Guizhou facility last July. Additionally,
we had a relatively low volume of products available for sale during most of the third quarter this year following the meaningful
growth in demand for our products in the first half of the year. However, our inventories have now been replenished as the first
143 tonnes of plasma and pastes purchased earlier this from Xinjiang Deyuan year have been fully processed. Since late September,
we began to deliver to the market products made from such raw materials. The majority of these products are expected to be delivered
to the market in 2016.”
Mr. Gao continued, “We recently
announced several important developments. We entered into a strategic cooperation agreement with Xinjiang Deyuan to source no
less than 500 tonnes of raw plasma over the next three years. Access to this additional source material represents a meaningful
growth catalyst for China Biologic, as we continue to expand our own collection capabilities. As part of this effort, we were
pleased to announce that we received approval in October to start plasma collection in our newly built branch collection facility
in Shandong Province. Also, in October, Shandong Taibang received approval from the CFDA to begin clinical trials on a new generation
IVIG product. We expect to be able to begin commercial production of the new generation IVIG in 2018 in our new operating facility
in Shandong.”
“As we anticipate a continued positive
trend in the fourth quarter, we are confident that we will be able to reach the high end of our full year sales guidance range
and we now expect to deliver net income results above our previous guidance. Looking forward to 2016, we will focus our operational
efforts on several key areas, which include: continuing to achieve double-digit growth in plasma collection volume, managing public
tenders in local markets to ensure stable or improved product pricing, further deepening our IVIG penetration in tier-one markets,
and overseeing the plasma collection from Xinjiang Deyuan’s plasma stations. Finally, we currently expect that the new Xi’an
Huitian facility, in which we have a minority equity interest, will obtain GMP certification and resume production in the second
half of 2016,” Mr. Gao concluded.
Third Quarter 2015 Financial Performance
Total sales, excluding foreign
currency impact, increased by 15.9% in RMB terms, or 14.4% in USD terms, to $78.8 million from $68.9 million in the third quarter
of 2015, compared with the same quarter of 2014. The increase was primarily attributable to increases in sales volume of major
plasma-based products.
During the
third quarter of 2015, human albumin and IVIG products remained the two largest sales contributors. The sales volume of human
albumin and IVIG products increased by 15.7% and 14.6%, respectively, in the reporting quarter. As a percentage of total sales,
sales from human albumin products increased to 38.7% in the third quarter of 2015 from 38.3% in the same quarter of 2014. Sales
from IVIG was 41.4% in the third quarter of 2015, as compared to 41.7% in the same quarter
of 2014.
The average price for human albumin products,
excluding foreign exchange impact, increased by approximately 1.2% in RMB terms, or decreased by approximately 0.2% in USD terms,
in the third quarter of 2015, compared with the same quarter of 2014. The average price for IVIG products, excluding foreign exchange
impact, increased by approximately 0.5% in RMB terms, or decreased by approximately 0.9% in USD terms, in the third quarter of
2015 compared with the same quarter of 2014.
Cost of sales was $28.0 million
in the third quarter of 2015, compared to $22.4 million in the same quarter of 2014. As a percentage of total sales, cost of sales
was 35.5%, as compared to 32.4% in the same quarter of 2014. The increase in cost of sales was mainly due to increased sales volume
and increased plasma collection costs, and from the higher cost of products made from the purchased raw plasma.
Gross
profit increased by 9.0% to $50.8 million in the third quarter of 2015 from $46.6 million
in the same quarter of 2014. Gross margin was 64.5% and 67.6% in the third quarter
of 2015 and 2014, respectively.
Total operating expenses in the
third quarter of 2015 increased by 32.8% to $15.8 million from $11.9 million in the same quarter of 2014 due to increases in general
and administrative expenses, mainly resulting from higher share-based compensation expenses. As a percentage of total sales, total
operating expenses increased to 20.0% in the third quarter of 2015 from 17.3% in the same quarter of 2014.
Selling expenses in the third quarter
of 2015 increased by 12.5% to $2.7 million from $2.4 million in the same quarter of 2014. As a percentage of total sales, selling
expenses remained relatively stable at 3.4%, compared with 3.5% in the same quarter of 2014.
General
and administrative expenses in the third quarter of 2015 were $11.5 million compared to $7.7 million in the same quarter of
2014. The increase in general and administrative expenses was mainly due to a $2.2 million increase in share-based compensation
expenses. As a percentage of total sales, general and administrative expenses increased to 14.6% in
the third quarter of 2015 from 11.2% in the third quarter of 2014.
Research and development expenses
in the third quarter of 2015 were $1.6 million, compared to $1.8 million in the same quarter of 2014. As a percentage of total
sales, research and development expenses decreased to 2.0% in the third quarter of 2015 from 2.6% in the same quarter of 2014.
Income from operations for the
third quarter of 2015 increased by 1.2% to $35.0 million from $34.6 million in the same period of 2014. Operating margin
decreased to 44.5% in the third quarter of 2015 from 50.2% in the same quarter of 2014.
Income tax expense in the third
quarter of 2015 was $6.0 million, compared to $7.0 million in the same quarter of 2014, representing a decrease of 14.3%. The
effective income tax rates were 16.8% and 19.9% in the third quarter of 2015 and 2014, respectively.
Net income
attributable to the Company increased by 13.9% to $22.9 million in the third quarter of 2015 from $20.1 million in the same
quarter of 2014. Net margin remained stable at 29.0%, compared to 29.1% in the same quarter of 2014. Fully diluted net
income per share increased to $0.82 in the third quarter of 2015 from $0.76 in the third quarter of 2014.
Non-GAAP adjusted net income attributable
to the Company increased by 23.6% to $26.2 million in the third quarter of 2015 from $21.2 million in the same quarter of
2014. Non-GAAP net margin increased to 33.2% from 30.8% in the same quarter of 2014. Non-GAAP adjusted net income per
diluted share increased to $0.94 in the third quarter of 2015 from $0.81 in the third quarter of 2014.
Non-GAAP adjusted net income and diluted
earnings per share in the third quarter of 2015 exclude $3.3 million of non-cash employee share-based compensation expenses.
First Nine Months 2015 Financial
Performance
Total sales, excluding foreign
currency impact, increased by 23.6% in RMB terms, or 23.2% in USD terms, to $228.2 million from $185.3 million, in the first nine
months of 2015 compared with the same period of 2014. The increase in sales was primarily driven by increases in sales volume
of major plasma-based products and placenta polypeptide. As a percentage of total sales, sales from human albumin products and
IVIG products were 37.5% and 43.6%, respectively, for the first nine months of 2015.
Cost of sales was $79.5 million
in the first nine months of 2015, compared to $59.0 million in the same period of 2014. Cost of sales as a percentage of total
sales was 34.8%, as compared to 31.8% in the same period of 2014.
Gross profit increased by 17.7%
to $148.7 million in the first nine months of 2015 from $126.3 million in the same period of 2014. Gross margin was 65.2%
in the first nine months of 2015, compared to 68.2% in the same period of 2014.
Total operating expenses in the
first nine months of 2015 increased by 11.2% to $38.7 million from $34.8 million in the same period of 2014. As a percentage of
total sales, total operating expenses decreased to 17.0% for the first nine months of 2015, from 18.8% in the same period of 2014.
Income from operations in the first
nine months of 2015 increased by 20.2% to $110.0 million from $91.5 million in the same period of 2014.
Income
tax expense in the first nine months of 2015 was $17.8 million, as compared to $16.8 million in the same period of 2014.
The effective income tax rate was 15.9% and 17.6% in the first nine months of 2015 and 2014, respectively.
Net income
attributable to the Company increased by 25.3% to $72.8 million for the first nine months of 2015, from $58.1 million in the
same period of 2014. Net margin was 31.9% and 31.3% for the first nine months of 2015 and 2014, respectively.
Non-GAAP
adjusted net income attributable to the Company was $79.7 million, or $2.94 per diluted share, for the first nine months of
2015, compared with $60.8 million, or $2.34 per diluted share, in the same period of 2014.
Non-GAAP adjusted net income and diluted
earnings per share for the first nine months of 2015 exclude $7.0 million of non-cash employee share-based compensation expenses.
As of September 30, 2015, the Company
had $142.7 million in cash and cash equivalents, primarily consisting of cash on hand and demand deposits, and $38.8 million
in time deposits.
Net cash provided by operating activities
for the first nine months of 2015 was $72.3 million, as compared to $64.1 million for the same period in 2014.
The increase in net cash provided by operating activities was primarily due to increases in net income, other payables
and accrued expenses, and decreases in prepayment and other current assets, partially offset by increases in accounts receivable
and inventories during the nine months ended September 30, 2015.
Accounts receivable increased by $16.2
million during the first nine months of 2015, as compared to $7.5 million during the same period in 2014, primarily due to the
extended credit terms granted to certain top-tier hospitals and distributors for human rabies immunoglobulin products.
Inventories increased by $26.1 million
in the first nine months of 2015, as compared to $8.7 million during the same period in 2014, primarily due to the increase of
plasma products and work-in-process derived from the source plasma and plasma pastes purchased from Xinjiang Deyuan.
Other payables and accrued expenses increased
by $4.2 million in the first nine months of 2015, as compared to $0.4 million during the same period in 2014, primarily due to
the individual income tax payable of $5.5 million withheld for employees and directors in connection with the vesting of certain
restricted stock in the third quarter of 2015.
The prepayment and other assets decreased
by $0.7 million in the first nine months of 2015, as compared to an increase of $8.6 million during the same period in 2014. During
the first nine months of 2014, Shandong Taibang made a payment totaling $5.0 million on behalf of a real estate developer to certain
employees under an employee housing development project.
Net cash used in investing activities
for the first nine months of 2015 was $55.8 million, as compared to $8.3 million for the same period in 2014. During the first
nine months of 2015, the Company paid $30.5 million for the acquisition of property, plant and equipment, intangible assets and
land use right for Shandong Taibang and Guizhou Taibang, provided a long-term loan of $28.5 million to Xinjiang Deyuan, and received
$2.5 million government grants related to property, plant and equipment. During the first nine months of 2014, the Company paid
$16.8 million for the acquisition of property, plant and equipment, intangible assets and land use right for Shandong Taibang
and Guizhou Taibang, received a refund of deposit of $1.6 million from the local government due to a decrease in the size of a
land parcel that was granted to the Company in Guizhou, and received $6.6 million upon the maturity of a time deposit.
Net cash provided by financing activities
for the first nine months of 2015 was $49.7 million, as compared to net cash used in financing activities of $124.5 million
for the same period in 2014. The net cash provided by financing activities for the first nine months of 2015 mainly consisted
of proceeds of $80.6 million from the follow-on offering of the Company’s common stock in June 2015 and $63.2 million from
the maturity of deposits used as security for bank loans, and proceeds of $7.2 million from stock options exercised, partially
offset by the repayment of bank loans totaling $97.9 million, as well as a dividend payment of $3.7 million held in escrow by
a trial court in connection with disputes with a minority shareholder of Guizhou Taibang. Net cash used in financing activities
for the first nine months of 2014 mainly consisted of a payment of $86.8 million for acquisition of non-controlling interest in
Guizhou Taibang and a payment of $70.0 million for share repurchase, partially offset by proceeds of $33.2 million from a follow-on
offering of the Company’s common stock in July 2014.
Financial Outlook
For the full year of 2015, the Company
reiterates its full year sales forecast, which was raised in May 2015, and raises its non-GAAP adjusted net income forecast, despite
the negative impact from foreign currency translation. The Company expects total sales to be on the high end of the range of $290
million to $295 million, which represents a growth of 19% to 21% over the past year. Due to better-than-expected operational efficiency
and a more profitable product mix during the first nine months of 2015, the Company now expects its full year non-GAAP adjusted
net income to be in the range of $98 million to $100 million as compared to its previous guidance of $95 million to $97 million,
representing a growth of 29% to 33% over the past year.
This revised guidance is based on an average
exchange rate during the reporting quarter of RMB6.244 = US$1.00, which is approximately 1% higher than the exchange rate used
in the Company’s previous guidance. It does not factor in the potential for further negative impact from foreign currency
translation.
This revised guidance assumes only organic
growth, excluding acquisitions, and necessarily assumes no significant product price changes during the remainder of 2015. This
forecast reflects the Company’s current and preliminary views, which are subject to change.
Conference Call
The Company will hold a conference call
at 7:30 a.m. ET on Wednesday, November 4, 2015 which is 8:30 p.m. Beijing Time on November 4, 2015 to discuss its third quarter
2015 results and answer questions from investors. Listeners may access the call by dialing:
US (Toll Free): |
1 888 346 8982 |
International: |
1 412 902 4272 |
Hong Kong (Toll Free): |
800 905 945 |
China (Toll Free): |
400 120 1203 |
A telephone replay will be available one
hour after the conclusion of the conference call through November 11, 2015. The dial-in details are:
US (Toll Free): |
1 877 344 7529 |
International: |
1 412 317 0088 |
Passcode: |
10075191 |
A live and archived webcast of the conference
call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com.
About China Biologic Products, Inc.
China Biologic Products, Inc. (NASDAQ:
CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company’s products are used as
critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency
related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products
through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guizhou Taibang Biological
Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products
to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website
www.chinabiologic.com.
Non-GAAP Disclosure
This news release contains non-GAAP financial
measures that exclude non-cash compensation expenses related to options and restricted shares granted to employees and directors
under the Company's 2008 Equity Incentive Plan. To supplement the Company's unaudited condensed consolidated financial statements
presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this
release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the
results relate to the Company's performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying
this news release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP
financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided
by other companies.
Safe Harbor Statement
This news release may contain certain
“forward-looking statements” relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements,
other than statements of historical fact included herein, are “forward-looking statements.” These forward-looking
statements are often identified by the use of forward-looking terminology such as “intend,” “believe,”
“expect,” “are expected to,” “will,” or similar expressions, and involve known and unknown
risks and uncertainties. Among other things, the Company’s plans regarding the production and sale of plasma products made
from the outsourced raw materials and the management’s quotations and forecast of the Company’s financial performance
in this news release contain forward-looking statements. Although the Company believes that the expectations reflected in these
forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove
to be incorrect.
Investors should not place undue reliance
on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results
could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including,
without limitation, quality inspection of outsourced source plasma, potential delay or failure to complete construction of new
collection facilities, potential inability to pass government inspection and certification process for existing and new facilities,
potential inability to achieve the designed collection capacities at the new collection facilities, potential inability to achieve
the expected operating and financial performance, potential inability to find alternative sources of plasma, potential inability
to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced
raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations
and those additional risks and uncertainties discussed in the Company’s periodic reports that are filed with the Securities
and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the
Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under
the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com
Financial statements follow.
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
| |
For the three months ended | | |
For the nine months ended | |
| |
September 30, | | |
September 30, | | |
September 30, | | |
September 30, | |
| |
2015 | | |
2014 | | |
2015 | | |
2014 | |
| |
USD | | |
USD | | |
USD | | |
USD | |
Sales | |
| 78,750,577 | | |
| 68,923,830 | | |
| 228,173,360 | | |
| 185,264,391 | |
Cost of sales | |
| 27,944,878 | | |
| 22,356,577 | | |
| 79,461,079 | | |
| 58,991,724 | |
Gross profit | |
| 50,805,699 | | |
| 46,567,253 | | |
| 148,712,281 | | |
| 126,272,667 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
Selling expenses | |
| 2,674,434 | | |
| 2,420,971 | | |
| 7,229,782 | | |
| 8,032,632 | |
General and administrative expenses | |
| 11,510,981 | | |
| 7,733,867 | | |
| 27,485,566 | | |
| 22,063,291 | |
Research and development expenses | |
| 1,595,140 | | |
| 1,788,286 | | |
| 3,984,447 | | |
| 4,700,647 | |
Income from operations | |
| 35,025,144 | | |
| 34,624,129 | | |
| 110,012,486 | | |
| 91,476,097 | |
| |
| | | |
| | | |
| | | |
| | |
Other income (expenses) | |
| | | |
| | | |
| | | |
| | |
Equity in (loss) income of an equity method investee | |
| (376,260 | ) | |
| (84,516 | ) | |
| (1,137,560 | ) | |
| 1,776,063 | |
Interest expense | |
| (101,290 | ) | |
| (1,048,177 | ) | |
| (1,533,971 | ) | |
| (2,532,341 | ) |
Interest income | |
| 1,383,142 | | |
| 1,722,967 | | |
| 4,227,124 | | |
| 5,043,169 | |
Total other income, net | |
| 905,592 | | |
| 590,274 | | |
| 1,555,593 | | |
| 4,286,891 | |
| |
| | | |
| | | |
| | | |
| | |
Earnings before income tax expense | |
| 35,930,736 | | |
| 35,214,403 | | |
| 111,568,079 | | |
| 95,762,988 | |
| |
| | | |
| | | |
| | | |
| | |
Income tax expense | |
| 6,052,353 | | |
| 7,007,650 | | |
| 17,792,164 | | |
| 16,832,025 | |
| |
| | | |
| | | |
| | | |
| | |
Net income | |
| 29,878,383 | | |
| 28,206,753 | | |
| 93,775,915 | | |
| 78,930,963 | |
| |
| | | |
| | | |
| | | |
| | |
Less: Net income attributable to noncontrolling interest | |
| 7,001,833 | | |
| 8,146,687 | | |
| 21,012,934 | | |
| 20,872,271 | |
| |
| | | |
| | | |
| | | |
| | |
Net income attributable to China Biologic Products, Inc. | |
| 22,876,550 | | |
| 20,060,066 | | |
| 72,762,981 | | |
| 58,058,692 | |
| |
| | | |
| | | |
| | | |
| | |
Net income per share of common stock: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 0.86 | | |
| 0.80 | | |
| 2.81 | | |
| 2.35 | |
Diluted | |
| 0.82 | | |
| 0.76 | | |
| 2.68 | | |
| 2.24 | |
Weighted average shares used in computation: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 25,992,776 | | |
| 24,548,042 | | |
| 25,280,538 | | |
| 24,325,752 | |
Diluted | |
| 27,056,215 | | |
| 25,787,106 | | |
| 26,488,730 | | |
| 25,568,515 | |
| |
| | | |
| | | |
| | | |
| | |
Net income | |
| 29,878,383 | | |
| 28,206,753 | | |
| 93,775,915 | | |
| 78,930,963 | |
| |
| | | |
| | | |
| | | |
| | |
Other comprehensive income: | |
| | | |
| | | |
| | | |
| | |
Foreign currency translation adjustment, net of nil income taxes | |
| (15,704,961 | ) | |
| (125,450 | ) | |
| (15,095,718 | ) | |
| (2,714,890 | ) |
| |
| | | |
| | | |
| | | |
| | |
Comprehensive income | |
| 14,173,422 | | |
| 28,081,303 | | |
| 78,680,197 | | |
| 76,216,073 | |
| |
| | | |
| | | |
| | | |
| | |
Less: Comprehensive income attributable to noncontrolling interest | |
| 4,015,428 | | |
| 8,081,309 | | |
| 18,302,111 | | |
| 20,327,295 | |
| |
| | | |
| | | |
| | | |
| | |
Comprehensive income attributable to China Biologic Products, Inc. | |
| 10,157,994 | | |
| 19,999,994 | | |
| 60,378,086 | | |
| 55,888,778 | |
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| |
September 30, | | |
September 30, | |
| |
2015 | | |
2014 | |
| |
USD | | |
USD | |
ASSETS | |
| | | |
| | |
Current Assets | |
| | | |
| | |
Cash and cash equivalents | |
| 142,660,409 | | |
| 80,820,224 | |
Restricted cash deposits | |
| - | | |
| 63,677,610 | |
Time deposits | |
| 38,822,808 | | |
| - | |
Accounts receivable, net of allowance for doubtful accounts | |
| 34,418,937 | | |
| 19,402,820 | |
Inventories | |
| 122,998,681 | | |
| 101,304,932 | |
Prepayments and other current assets, net of allowance for doubtful accounts | |
| 25,063,917 | | |
| 14,781,658 | |
Total Current Assets | |
| 363,964,752 | | |
| 279,987,244 | |
| |
| | | |
| | |
Property, plant and equipment, net | |
| 96,991,796 | | |
| 80,230,888 | |
Land use rights, net | |
| 15,162,367 | | |
| 11,909,136 | |
Deposits related to land use rights | |
| 12,322,732 | | |
| 12,792,355 | |
Restricted cash and cash deposits, excluding current portion | |
| - | | |
| 40,230,250 | |
Equity method investment | |
| 9,073,773 | | |
| 18,221,777 | |
Loan receivable | |
| 28,296,000 | | |
| - | |
Other non-current assets | |
| 2,948,377 | | |
| 3,475,442 | |
Total Assets | |
| 528,759,797 | | |
| 446,847,092 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current Liabilities | |
| | | |
| | |
Short-term bank loans, including current portion of long-term bank loans | |
| - | | |
| 57,902,600 | |
Accounts payable | |
| 5,299,128 | | |
| 4,829,350 | |
Other payables and accrued expenses | |
| 53,478,778 | | |
| 49,692,757 | |
Income tax payable | |
| 7,523,273 | | |
| 8,257,133 | |
Total Current Liabilities | |
| 66,301,179 | | |
| 120,681,840 | |
| |
| | | |
| | |
Long-term bank loans, excluding current portion | |
| - | | |
| 40,000,000 | |
Deferred income | |
| 4,750,977 | | |
| 2,765,024 | |
Other liabilities | |
| 8,031,697 | | |
| 8,138,498 | |
Total Liabilities | |
| 79,083,853 | | |
| 171,585,362 | |
| |
| | | |
| | |
Stockholders’ Equity | |
| | | |
| | |
Common stock: | |
| | | |
| | |
par value $0.0001;100,000,000 shares authorized; 28,784,953 and 27,865,871
shares issued at September 30, 2015 and December 31, 2014, respectively; 26,530,249 and 24,806,167 shares outstanding at September 30, 2015 and December 31, 2014, respectively | |
| 2,878 | | |
| 2,787 | |
Additional paid-in capital | |
| 99,518,736 | | |
| 24,008,281 | |
Treasury stock: 2,254,704 and 3,059,704 shares at September 30, 2015 and December 31, 2014, respectively, at cost | |
| (56,425,094 | ) | |
| (76,570,621 | ) |
| |
| | | |
| | |
Retained earnings | |
| 317,424,372 | | |
| 244,661,391 | |
Accumulated other comprehensive income | |
| 7,600,294 | | |
| 19,985,189 | |
Total equity attributable to China Biologic Products, Inc. | |
| 368,121,186 | | |
| 212,087,027 | |
| |
| | | |
| | |
Noncontrolling interest | |
| 81,554,758 | | |
| 63,174,703 | |
| |
| | | |
| | |
Total Stockholders’ Equity | |
| 449,675,944 | | |
| 275,261,730 | |
| |
| | | |
| | |
Commitments and contingencies | |
| - | | |
| - | |
| |
| | | |
| | |
Total Liabilities and Stockholders’ Equity | |
| 528,759,797 | | |
| 446,847,092 | |
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| |
For the nine months ended | |
| |
September 30, | | |
September 30, | |
| |
2015 | | |
2014 | |
| |
USD | | |
USD | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | | |
| | |
Net income | |
| 93,775,915 | | |
| 78,930,963 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |
| | | |
| | |
Depreciation | |
| 6,103,812 | | |
| 5,136,783 | |
Amortization | |
| 637,301 | | |
| 558,991 | |
Loss on sale of property, plant and equipment and land use rights | |
| 363,857 | | |
| 152,638 | |
Allowance (Reversal) for doubtful accounts - accounts receivable | |
| 35,162 | | |
| (24,462 | ) |
Allowance for doubtful accounts - other receivables and prepayments | |
| 793 | | |
| - | |
Write-down of obsolete inventories | |
| 16,650 | | |
| 9,092 | |
Deferred tax expense | |
| (55,232 | ) | |
| 934,986 | |
Share-based compensation | |
| 7,640,894 | | |
| 3,331,299 | |
Equity in loss (income) of an equity method investee | |
| 1,137,560 | | |
| (1,776,063 | ) |
Excess tax benefits from share-based compensation arrangements | |
| (288,681 | ) | |
| (760,869 | ) |
Change in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (16,229,405 | ) | |
| (7,510,078 | ) |
Prepayment and other current assets | |
| 742,586 | | |
| (8,602,273 | ) |
Inventories | |
| (26,058,886 | ) | |
| (8,705,670 | ) |
Accounts payable | |
| 659,077 | | |
| 396,647 | |
Other payables and accrued expenses | |
| 4,240,643 | | |
| 358,075 | |
Deferred income | |
| (284,053 | ) | |
| (149,296 | ) |
Income tax payable | |
| (170,407 | ) | |
| 1,827,163 | |
Net cash provided by operating activities | |
| 72,267,586 | | |
| 64,107,926 | |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Payment for property, plant and equipment | |
| (26,310,114 | ) | |
| (13,925,010 | ) |
Payment for intangible assets and land use right | |
| (4,199,308 | ) | |
| (2,834,220 | ) |
Refund of deposits related to land use right | |
| - | | |
| 1,635,200 | |
Proceeds upon maturity of time deposit | |
| - | | |
| 6,608,612 | |
Proceeds from sale of property, plant and equipment and land use rights | |
| 741,980 | | |
| 216,071 | |
Long-term loan lent to a third party | |
| (28,450,202 | ) | |
| - | |
Receipt of government grants related to property and equipment | |
| 2,452,864 | | |
| - | |
Net cash used in investing activities | |
| (55,764,780 | ) | |
| (8,299,347 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Proceeds from stock option exercised | |
| 7,220,483 | | |
| 2,258,285 | |
Proceeds from short-term bank loans | |
| - | | |
| 44,500,340 | |
Repayment of bank loans | |
| (97,910,360 | ) | |
| (38,605,600 | ) |
Proceeds from long-term bank loans | |
| - | | |
| 70,000,000 | |
Payment for deposit as security for long-term bank loans | |
| - | | |
| (72,290,922 | ) |
Payment for deposit as security for short-term bank loans | |
| - | | |
| (31,881,083 | ) |
Maturity of deposit as security for long-term bank loans | |
| - | | |
| 30,370,670 | |
Maturity of deposit as security for short-term bank loans | |
| 63,152,258 | | |
| - | |
Payment for share repurchase | |
| - | | |
| (70,000,000 | ) |
Excess tax benefits from share-based compensation arrangements | |
| 288,681 | | |
| 760,869 | |
Dividend paid by subsidiaries to noncontrolling interest shareholders | |
| - | | |
| (6,035,226 | ) |
Net proceeds from reissuance of treasury stock | |
| 80,583,959 | | |
| 33,212,518 | |
Acquisition of noncontrolling interest | |
| - | | |
| (86,830,499 | ) |
Dividend to the trial court to be held in escrow as to dispute with Jie'an | |
| (3,690,814 | ) | |
| - | |
Net cash provided by (used in) financing activities | |
| 49,644,207 | | |
| (124,540,648 | ) |
| |
| | | |
| | |
EFFECTS OF FOREIGN EXCHANGE RATE CHANGE ON CASH | |
| (4,306,828 | ) | |
| (827,626 | ) |
| |
| | | |
| | |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | |
| 61,840,185 | | |
| (69,559,695 | ) |
| |
| | | |
| | |
Cash and cash equivalents at beginning of period | |
| 80,820,224 | | |
| 144,138,487 | |
| |
| | | |
| | |
Cash and cash equivalents at end of period | |
| 142,660,409 | | |
| 74,578,792 | |
| |
| | | |
| | |
Supplemental cash flow information | |
| | | |
| | |
Cash paid for income taxes | |
| 18,073,863 | | |
| 14,098,003 | |
Cash paid for interest expense | |
| 1,426,883 | | |
| 2,108,667 | |
Noncash investing and financing activities: | |
| | | |
| | |
Acquisition of property, plant and equipment included in payables | |
| 1,990,043 | | |
| 2,988,146 | |
CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
| |
For the three months ended | |
| |
September 30, | | |
September 30, | |
| |
2015 | | |
2014 | |
| |
USD | | |
USD | |
Adjusted Net Income Attributable to the Company - Non GAAP | |
| 26,184,686 | | |
| 21,236,986 | |
Diluted EPS - Non GAAP | |
| 0.94 | | |
| 0.81 | |
Non-cash employee stock compensation | |
| (3,308,136 | ) | |
| (1,176,920 | ) |
Net Income Attributable to the Company | |
| 22,876,550 | | |
| 20,060,066 | |
Weighted average number of shares used in computation of Non GAAP diluted EPS | |
| 27,056,215 | | |
| 25,787,106 | |
| |
For the nine months ended | |
| |
September 30, | | |
September 30, | |
| |
2015 | | |
2014 | |
| |
USD | | |
USD | |
Adjusted Net Income Attributable to the Company - Non GAAP | |
| 79,717,719 | | |
| 60,831,362 | |
Diluted EPS - Non GAAP | |
| 2.94 | | |
| 2.34 | |
Non-cash employee stock compensation | |
| (6,954,738 | ) | |
| (2,772,670 | ) |
Net Income Attributable to the Company | |
| 72,762,981 | | |
| 58,058,692 | |
Weighted average number of shares used in computation of Non GAAP diluted EPS | |
| 26,488,730 | | |
| 25,568,515 | |
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024